Skip to main content

DarioHealth Corp.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Interim Statements of Cash Flows (Unaudited)

U.S. dollars in thousands

​​​​​​​
​ · ​ · Six months ended
​ · ​ · June 30,
​ · ​ ​ ​ · 2026 · ​ ​ ​ · 2025
Cash flows from operating activities:​​​​​​
Net loss​$(16,173)​$(22,217)
Adjustments required to reconcile net loss to net cash used in operating activities:​​​​
Stock-based compensation​2,073​4,377
Change in operating lease right of use assets​237​204
Amortization of acquired intangible assets​931​1,884
Depreciation and impairment​108​174
Change in fair value of warrant liability​(185)​(825)
Accrued interest on short term bank deposits​​(63)​​—
Non-cash financial expenses​265​2,665
Changes in operating assets and liabilities:​​​​​​
Decrease in trade receivables, net​595​2,248
Increase in other accounts receivable, prepaid expense and long-term assets​(364)​(484)
Decrease in inventories​597​143
Increase in trade payables​232​334
Increase (decrease) in other accounts payable and accrued expenses​83​(858)
Decrease in deferred revenues​(193)​(856)
Decrease in operating lease liabilities​(201)​(147)
Other​(50)​654
Net cash used in operating activities​(12,108)​(12,704)
​​​​​​​
Cash flows from investing activities:​​​​
Investment in short term bank deposit​​(9,250)​​—
Proceeds from maturity of short-term bank deposit​​6,200​​—
Purchase of property and equipment​(69)​(75)
Disposals of property and equipment​​6​​—
Net cash used in investing activities​(3,113)​(75)
​​​​​​​
Cash flows from financing activities:​​​​
Proceeds from AT-The-Market ("ATM") equity offerings​​104​​—
Issuance costs related to ATM equity offerings​​(104)​​—
Proceeds from issuance of common stock and preferred stock, net of issuance costs​—​6,754
Proceeds from borrowings on credit agreement​​—​​31,700
Repayment of long-term loan​​—​​(31,515)
Net cash provided by financing activities​—​6,939
​​​​​​​
Decrease in cash, cash equivalents and restricted cash and cash equivalents​(15,221)​(5,840)
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents​​52​​30
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period​21,803​27,764
Cash, cash equivalents and restricted cash and cash equivalents at end of period​$6,634​$21,954
Supplemental disclosure of cash flow information:​​​​
Cash paid during the period for interest on long-term loan​$1,930​$1,250
Non-cash activities:​​​​
Exercise of pre-funded warrants to common stock​$1,266​$1,750
Right-of-use assets obtained in exchange for lease liabilities​$549​$—
Purchase of property and equipment on credit​$13​$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.